Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting^*

References

• Liau CT, Chu NM, Liu HE, et al. Incidence of chemotherapyinduced nausea and vomiting in Taiwan: physicians’ and nurses’ estimation vs. patients’ reported outcomes. Support Care Cancer 2005;13:277–86
   PubMed Web of Science ®Google Scholar
• Ihbe-Heffinger A, Ehlken B, Bernard R, et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 2004;15:526–36
   Google Scholar
• Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 1999;17:2971–94
   PubMed Web of Science ®Google Scholar
• Gandara DR, Harvey WH, Monaghan GG, et al. The delayedemesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo. Semin Oncol 1992;19:67–71
   PubMed Web of Science ®Google Scholar
• Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14:1570–7
   Google Scholar
• Grelot L, Dapzol J, Esteve E, et al. Potent inhibition of both the acute and delayed emetic responses to cisplatin in piglets treated with GR205171, a novel highly selective tachykinin NK1 receptor antagonist. Br J Pharmacol 1998;124:1643–50
   PubMed Web of Science ®Google Scholar
• Hale JJ, Mills SG, MacCoss M, et al. Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl) phenylethoxy)-3- (S) - (4- f luoro)phenyl -4- (3-oxo-1,2,4- t r iazol -5-yl ) methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist. J Med Chem 1998;41:4607–14
   PubMed Web of Science ®Google Scholar
• Hesketh PJ. Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting. Support Care Cancer 2001;9:350–4
   PubMed Web of Science ®Google Scholar
• Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24:2932–47
   PubMed Web of Science ®Google Scholar
• Van Sickle MD, Oland LD, Mackie K, et al. Delta9-tetrahydrocannabinol selectively acts on CB1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am J Physiol Gastrointest Liver Physiol 2003;285:G566–76
   PubMed Web of Science ®Google Scholar
• Darmani NA. Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew. Pharmacol Biochem Behav 2001;69:239–49
   PubMed Web of Science ®Google Scholar
• Darmani NA, Crim JL. Delta-9-tetrahydrocannabinol differentially suppresses emesis versus enhanced locomotor activity produced by chemically diverse dopamine D2/D3 receptor agonists in the least shrew (Cryptotis parva). Pharmacol Biochem Behav 2005;80:35–44
   PubMed Web of Science ®Google Scholar
• Darmani NA, Johnson JC. Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis. Eur J Pharmacol 2004;488:201–12
   PubMed Web of Science ®Google Scholar
• Tramer MR, Carroll D, Campbell FA, et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001;323:16–21
   PubMed Web of Science ®Google Scholar
• Beckwith C, Mullin S. Prevention and management of chemo-therapy-induced nausea and vomiting. Part 1. Hosp Pharm 2001;36:67–80
   Google Scholar
• Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–55
   PubMed Web of Science ®Google Scholar
• Marinol (dronabinol). Full Prescribing Information, Solvay Pharmaceuticals, Inc, Marietta, GA, 2001
   Google Scholar
• Zofran (ondansetron). Full Prescribing Information, Glaxo Smith Kline, Australia, 2003
   Google Scholar
• McCorkle R, Young K. Development of a symptom distress scale. Cancer Nurs 1978;1:373–8
   PubMedGoogle Scholar
• Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemo-therapy-induced nausea and emesis after modern antiemetics. Cancer 2004;100:2261–8
   PubMed Web of Science ®Google Scholar
• Navari RM. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting – two new agents. J Support Oncol 2003;1:89–103
   PubMedGoogle Scholar
• McCabe M, Smith FP, Macdonald JS, et al. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. Invest New Drugs 1988;6:243–6
   PubMed Web of Science ®Google Scholar
• Sallan SE, Zinberg NE, Frei E, 3rd. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 1975;293: 795–7
   Google Scholar
• Sallan SE, Cronin C, Zelen M, Zinberg NE. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med 1980;302:135–8
   PubMed Web of Science ®Google Scholar
• Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Ann Oncol 1998;9:811–19
   Google Scholar
• ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm 1999;56:729–64
   PubMed Web of Science ®Google Scholar